Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tedizolid phosphate versus linezolid for acute bacterial skin and skin structure infections
2011-002860-26Phase 3Completed
- Sponsor
- Trius Therapeutics
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) comparing Tedizolid phosphate IV-to-oral with Linezolid IV-to-oral (2 arms). Primary endpoint: Early clinical response rate at 48-72 hours. Started Sep 2011; status: completed.
02
Drugs
tedizolidlinezolid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on 2011-002860-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002860-26.